Return to homepagePandemic Pact

University of Oxford, Leipzig Institute for Drug Discovery, Moderna

  • Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
  • Total publications:0 publications

Grant number: CEPI-1671

Grant search

Key facts

  • Disease

    Unspecified

  • Start & end year

    2026

  • Known Financial Commitments (USD)

    $26,700,000

  • Funder

    Coalition for Epidemic Preparedness Innovations (CEPI)

  • Principal Investigator

    N/A

  • Research Location

    99

  • Lead Research Institution

    University of Oxford, Leipzig Institute for Drug Discovery, Moderna

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Backed by up to $26.7 million in funding from CEPI and the European Union’s Horizon Europe programme, researchers at the Oxford Vaccine Group and the Pandemic Sciences Institute will work with partners to design and test multivalent vaccine candidates that aim to protect individuals from a wide range of filoviruses. AI-designed immunogens, developed by the Institute for Drug Discovery in Leipzig, will be added to both the University of Oxford’s ChAdOx viral vector vaccine platform and Moderna’s mRNA vaccine platform and tested head-to-head in preclinical studies to find the optimal combinations. Should a suitably promising vaccine candidate emerge from these studies, it could then be evaluated for safety and immunogenicity in Phase I clinical trials, potentially providing crucial proof-of-concept data for broadly protective filovirus vaccines.